Atea Pharmaceuticals Inc. (AVIR) News
Filter AVIR News Items
AVIR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AVIR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AVIR News From Around the Web
Below are the latest news stories about ATEA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AVIR as an investment opportunity.
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco, CA. A live webcast |
US Penny Stocks To Watch In December 2024As the U.S. stock market heads into the Christmas break, optimism is in the air with major indices like the Nasdaq Composite and S&P 500 posting gains, sparking hopes for a Santa Claus rally to close out 2024. Penny stocks may be considered a throwback term, yet they continue to offer intriguing opportunities for those looking beyond well-known names. Often representing smaller or newer companies, these stocks can provide growth potential at lower price points when supported by strong... |
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic PartnershipsBOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has engaged Evercore, a global independent investment bank, to identify potential opportunities to enhance shareholder value, including the exploration of strategic partnerships related to its Phase 3-ready program for the treatme |
Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvirAtea Pharmaceuticals (AVIR) announced that the Company’s Phase 2 study of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for treatment of hepatitis C virus met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment. Primary endpoint results demonstrated a 98% SVR12 rate in the per-protocol treatment adherent patient population after eight weeks of treatment with a regimen of bemnifosbuvir and ruzasvir. |
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C StudyOn Wednesday, Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) released Phase 2 study data from the regimen of bemnifosbuvir and ruzasvir for the hepatitis C virus infection that causes liver swelling and can lead to serious liver damage. The study met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment (SVR12). Primary endpoint results demonstrated a 98% (208/213) SVR12 rate in the per-protocol treatment adherent patient population after eight weeks of treatment |
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration Regimen Was Generally Safe and Well-Tolerated Global Phase 3 Program Initiation Expected Early in 2025 BOSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today |
Atea plans Phase 3 study for hepatitis C drug after mid-stage resultsThe struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier treatment regimen. |
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx ConferenceBOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the 7th Annual Evercore He |
Promising US Penny Stocks To Watch In November 2024As U.S. stock futures rise and major indexes approach record highs, investors are increasingly looking for opportunities in various sectors of the market. Penny stocks, while often seen as a relic from past trading eras, remain relevant due to their potential for growth when supported by strong financials. These smaller or newer companies can offer a unique blend of affordability and growth potential, making them an intriguing option for those seeking hidden value in the market. |
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?Here is how Atea Pharmaceuticals, Inc. (AVIR) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year. |